EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 19-Sep-2025 15:11 ET (19-Sep-2025 19:11 GMT/UTC)

Oral bacterial and fungal microbiome and subsequent risk for pancreatic cancer

JAMA Network
Peer-Reviewed Publication

About The Study: In this cohort study, oral bacteria and fungi were significant risk factors for pancreatic cancer development. Oral microbiota hold promise as biomarkers to identify individuals at high risk of pancreatic cancer, potentially contributing to personalized prevention.

Journal: JAMA Oncology

Oral microbes linked to increased risk of pancreatic cancer

NYU Langone Health / NYU Grossman School of Medicine
Peer-Reviewed Publication

Twenty-seven species of bacteria and fungi among the hundreds that live in people’s mouths have been collectively tied to a 3.5 times greater risk of developing pancreatic cancer, a study led by NYU Langone Health and its Perlmutter Cancer Center shows.

Journal: JAMA Oncology
Funder: NIH/National Institutes of Health, NIH/National Institutes of Health, NIH/National Institutes of Health, NIH/National Institutes of Health, NIH/National Institutes of Health

IU scientists identify dual protein targets to weaken pancreatic cancer defenses

Indiana University
Peer-Reviewed Publication

New research uncovers link between two key proteins that help pancreatic cancer resist treatment, opening the door to more effective therapies for aggressive cancers

Journal: Redox Biology

Study reveals efficacy of nicotinamide for skin cancer prevention

Vanderbilt University Medical Center
Peer-Reviewed Publication

The researchers compared 12,287 patients who received the treatment with 21,479 who did not. Overall, there was a 14% reduction in skin cancer risk. When nicotinamide was taken after a first skin cancer, the risk reduction rose to 54%, but the benefit declined with treatment initiation following subsequent skin cancers. The risk reduction was much larger for squamous cell carcinoma.

Journal: JAMA Dermatology
Funder: Department of Veterans' Affairs

Serum-derived hsa_circ_101555 as a diagnostic biomarker in non-hepatocellular carcinoma chronic liver disease

Xia & He Publishing Inc.
Peer-Reviewed Publication

Circular RNAs (circRNAs) are non-coding RNAs characterized by a strictly closed-loop covalent structure. They are abundantly detected in various cells due to their conserved nature. Studies have reported their potential association with chronic liver disease (CLD), including hepatitis, cirrhosis, and hepatocellular carcinoma (HCC), with possible roles as diagnostic and prognostic markers. This study aimed to analyze the potential use of serum-derived hsa_circ_101555 as a diagnostic tool for CLD without HCC, and to compare it with other known non-invasive parameters for liver disease severity and inflammation. Additionally, it aimed to evaluate its expression among non-HCC CLD patients, CLD with HCC cases reported in our published (phase I) study, and healthy controls.

Journal: Gene Expression

New findings explain how a mutation in a cancer-related gen causes pulmonary fibrosis

Centro Nacional de Investigaciones Oncológicas (CNIO)
Peer-Reviewed Publication

A research group from the National Cancer Research Centre (CNIO) has found that an alteration in the POT1 gene prevents lung tissue from regenerating, which over time makes breathing difficult.

The mutation prevents telomeres, the structures that protect chromosomes, from repairing.

According to the authors, understanding the effect of mutations like this “is critical to developing personalised therapies” against ‘telomere syndromes’, a group of diseases that includes pulmonary fibrosis and several cancer types.

Journal: Genes & Development
Funder: European Research Council

PANoptosis: A new allyin the fight against liver cancer

China Anti-Cancer Association
Peer-Reviewed Publication

Liver cancer, particularly hepatocellular carcinoma (HCC), remains one of the deadliest cancers, driven by high recurrence and resistance to therapy.

Journal: Cancer Biology & Medicine

Korea University study identifies age 70 as cutoff for chemotherapy benefit in colorectal cancer

Korea University College of Medicine
Peer-Reviewed Publication

Colorectal cancer is one of the most common and deadly cancers worldwide, and treatment decisions for older patients remain highly debated. Now, researchers have found that oxaliplatin-based chemotherapy significantly improves survival only in stage III colorectal cancer patients aged 70 or younger. For patients over 70, the drug offered no survival advantage and led to higher rates of treatment discontinuation due to toxicity. Importantly, stage II patients showed no survival benefit at any age.

Journal: JAMA Network Open

Graz University of Technology opens up new avenues in lung cancer research with digital cell twin

Graz University of Technology
Reports and Proceedings

An enhanced computer model is now helping to provide fresh insights into cancer-cell growth and how it can be stopped. The digital cell model represents another step towards individualised cancer treatment.

Journal: Clinical and Translational Medicine
Funder: Österreichische Krebshilfe Steiermark

New insights into melanoma plasticity uncover a critical role of iron metabolism

Vlaams Instituut voor Biotechnologie
Peer-Reviewed Publication

VIB researchers and colleagues have discovered a mechanism through which melanoma cells adapt and switch between two major proliferative and invasive states, revealing promising new targets for cancer therapy. The study, published in Nature Metabolism, reveals that alterations in iron metabolism and organelle crosstalk are central to melanoma cell plasticity—a key factor in tumor progression and resistance to treatment.

Journal: Nature Metabolism
Funder: FWO, Stichting Tegen Kanker, KU Leuven

1
2
3
4